This session will focus specifically on the role of automation and digital systems in improving consistency, throughput, and scalability in oligonucleotide manufacturing. Key challenges include integrating automated synthesis with downstream purification, enabling real-time process monitoring, and leveraging digital data to support process understanding and control. Discussion will address implementation barriers, data standardization, and the use of digital tools to support tech transfer and GMP operations. Participants will explore how automation and digitalization can reduce manual variability, shorten development timelines, and support flexible manufacturing models for next-generation oligonucleotide therapies.